



Østergaard, M. V., Ribeiro Pinto, V., Stevenson, K., Worm, J., Fink, L. N., & Coward, R. (2017). DBA2J db/db mice are susceptible to early albuminuria and glomerulosclerosis that correlates with systemic insulin resistance. *AJP - Renal Physiology*, 312(2), F312-F321. <https://doi.org/10.1152/ajprenal.00451.2016>

Peer reviewed version

Link to published version (if available):  
[10.1152/ajprenal.00451.2016](https://doi.org/10.1152/ajprenal.00451.2016)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via American Physiological Society at DOI: 10.1152/ajprenal.00451.2016. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**DBA2J db/db mice are susceptible to early albuminuria and glomerulosclerosis that correlates with systemic insulin resistance**

Mette V. Østergaard<sup>1,2</sup>, Vanda Pinto<sup>2</sup>, Kirsty Stevenson<sup>3</sup>, Jesper Worm<sup>1</sup>, Lisbeth N. Fink<sup>1</sup>, Richard J.M. Coward<sup>2</sup>

<sup>1</sup>Global Research, Novo Nordisk A/S, Måløv, Denmark

<sup>2</sup>Bristol Renal, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom

<sup>3</sup>Department of Biochemistry, Bristol Royal Infirmary, Bristol, United Kingdom.

**Running head:** Diabetic nephropathy in the db/db DBA/2J mouse

**Corresponding author:**

Professor Richard J.M. Coward

Bristol Renal, School of Clinical Sciences

Whitson Street, Bristol

BS1 3NY, United Kingdom

Phone: +44 (0) 117 331 3117

E-mail: richard.coward@bristol.ac.uk

**Keywords:** insulin resistance, diabetic nephropathy, kidney injury, albuminuria, genetic

background

## Abstract

*Introduction:* Diabetic nephropathy (DN) is the leading cause of kidney failure in the world. To understand important mechanisms underlying this condition, and to develop new therapies, good animal models are required. In mouse models of type-1 diabetes, the DBA/2J strain has been shown to be more susceptible to develop kidney disease than other common strains. We hypothesized this would also be the case in type-2 diabetes. *Methods:* We studied db/db and wt DBA/2J mice and compared these with the db/db BLKS/J mouse, which is currently the most widely used type-2 DN model. Mice were analyzed from age 6 to 12 weeks for systemic insulin resistance, albuminuria and glomerular histopathological and ultra-structural changes. *Results:* Body weight and non-fasted blood glucose were increased by 8-weeks in both genders, while systemic insulin resistance commenced by 6-weeks in female and 8-weeks in male db/db DBA/2J mice. The urinary albumin-to-creatinine ratio (ACR) was closely linked to systemic insulin resistance in both sexes and was increased ~50-fold by 12 weeks age in the db/db DBA/2J cohort. Glomerulosclerosis, foot process effacement and glomerular basement membrane thickening were observed at 12-weeks of age in db/db DBA/2J mice. Compared to db/db BLKS/J mice, db/db DBA/2J mice had significantly increased levels of urinary ACR, but similar glomerular histopathological and ultrastructural changes. *Conclusion:* The db/db DBA/2J mouse is a robust model of early stage albuminuric DN and its levels of albuminuria correlate closely with systemic insulin resistance. This mouse model will be helpful in defining early mechanisms of DN and ultimately the development of novel therapies.

## Introduction

Diabetic nephropathy (DN) is the leading cause of kidney failure in the world with over half of patients in the United States entering the end stage renal failure (ESRF) program for this reason. It is increasing at alarming rates throughout both the developed and developing worlds predominantly due to the global epidemic increase in type-2 diabetes (33) caused by sedentary lifestyles, diet and obesity (16). DN generally has a well-defined natural history and initially affects the glomerulus manifesting as hyperfiltration and microalbuminuria (30-300 mg albumin/24 hours) before progressing to macroalbuminuria (more than 300mg/albumin/ 24 hours). Macroalbuminuria usually heralds the start of declining glomerular filtration and associated tubulointerstitial fibrosis. The best current biomarker for kidney involvement in DN is the presence of micro or macroalbuminuria. These may be helpful in identifying affected kidneys and allow therapies to be started early before established fibrotic kidney disease is present. It is now clear that systemic insulin resistance is closely linked to DN progression in both type-1 (25) and type-2 DN (12) so finding models that mimic this would be beneficial in understanding mechanisms and ultimately identifying therapeutic targets to stop early DN from progressing. To understand the mechanisms underlying DN it is vital to have good cellular and animal models of DN, but these are currently suboptimal.

In diabetic patients, multiple genetic factors modulate the risk of developing DN (11, 26). Similarly in mice, the susceptibility to kidney injury is influenced by the inbred mouse strain used as have been illustrated in models of type-1 diabetes. At one extreme, the C57BL/6J strain is resistant to DN in the STZ-induced and the *Ins2*<sup>+/C96Y</sup> (Akita) models of diabetes as diabetic mice develop only subtle albuminuria with slow advancement of mesangial matrix expansion (13, 14). At the other extreme, the DBA/2J strain displays enhanced susceptible to DN and develop exaggerated urinary albumin excretion compared with other common inbred mouse strains including C57BL/6J, A/J and Sv129 in the STZ-induced (13, 28) and the Akita (5, 14) models.

The genetic background also influences the susceptibility to DN in the db/db mouse model, where an autosomal recessive mutation in the *Lepr* gene (i.e. the diabetogenic *db* allele) renders mice obese, insulin resistant and diabetic (7). The phenotypical manifestations of the *db* allele were first described in the C57BLKS/J (BLKS/J) strain (17), which is a genetic composite between the DN resistant C57BL/6J and DN susceptible DBA/2J strains in addition to alleles from at least three other strains including SV129 (22). The db/db BLKS/J mouse is susceptible to DN and develops significant albuminuria by 8 weeks of age (2, 6, 23, 30) along with histopathological features of early DN by 12-weeks of age including glomerular enlargement (21, 23) and glomerulosclerosis (6, 21, 23). Despite having more than 70% of its genome derived from the DN resistant C57BL/6J strain, the db/db BLKS/J mouse constitutes a robust model of the early changes in human DN (1) and DBA/2J-derived genetic components may be responsible for the susceptibility to DN in this strain. Although the *db* allele has been introduced in the DBA/2J strain (19), the susceptibility to albuminuric kidney disease and development of DN in the db/db DBA/2J mouse remains to be explored in detail.

Here we describe the development of early DN in the db/db DBA/2J mouse to investigate the influence of genetic background on the susceptibility to kidney injury during the transition from prediabetes to diabetes in the db/db mouse model. We hypothesize that the DBA/2J strain display augmented albuminuria as well as histopathological and ultrastructural changes compared to the commonly used BLKS/J strain. Using female and male db/db DBA/2J mice alongside age- and gender-matched lean controls, we characterized the development of metabolic parameters (i.e. body weight, blood glucose and systemic insulin sensitivity) and the development of kidney injury (i.e. urinary albumin-to-creatinine ratio, glomerulosclerosis score and ultrastructural features). We investigated the effects of genetic background on DN by comparing our findings to a cohort of db/db BLKS/J mice.

## Materials & Methods

### *Mouse breeding and housing*

Heterozygous db/wt DBA/2J (D2.BKS(D)-*Lep<sup>db</sup>*/J) breeders were purchased from The Jackson Laboratory (Bar Harbor, ME, US) to breed female and male db/db mice and lean wild type offspring *in house*. To obtain adequate numbers of lean control mice, both db/wt and wt/wt mice were included in the experiment - hereinafter referred to as wt mice. Data on outcome of breeding are presented in Table 1. Male db/db and heterozygous db/wt BLKS/J (BKS.Cg-*Dock7m* +/+ *Lep<sup>db</sup>*/J) mice were purchased from Charles River (Calco, Italy).

All mice were housed in a 12/12 h light/dark cycle with free access to standard chow (EURodent Diet 22%, percentage of energy: protein 25.9%, fat 9.3%, carbohydrate 64.8%; LabDiet, St. Louis, MO, US) and water. All animal procedures were carried out according to the Guidance of the Operation of the Animals (Scientific Procedures) Act 1986 and all protocols were approved by the Home Office (London, UK).

### *Characterization of metabolic parameters*

To characterize the early metabolic phenotype of the db/db model, a total of 24 db/db (12 females, 12 males) and 15 wt (8 females, 7 males) DBA/2J mice were kept from 6 and up to 12 weeks of age, whereas 6 male db/db and 6 wt BLKS/J mice were kept from 8 to 12 weeks of age. Body weight and non-fasted blood glucose were measured biweekly. Blood glucose was measured in tail vein blood using an Accu-Chek Aviva Nano portable glucometer (Roche, Indianapolis, IN, US).

Systemic insulin sensitivity was assessed by insulin tolerance tests (ITT) at 6, 8 and 12 weeks in DBA/2J mice, and at 8 and 12 weeks in BLKS/J mice. Briefly, mice were fasted for 6 h with free access to water. Human insulin (Novo Nordisk, Måløv, Denmark) was injected intraperitoneally (i.p.) at a dose of 0.20 IU/kg in females and 0.50 IU/kg in males, respectively. Blood glucose was

measured in tail vein blood before (T=0 min) and 15, 30, 45, 60 and 90 min after insulin injection using an Accu-Chek Aviva Nano portable glucometer. The applied doses of insulin were empirically determined prior to ITTs as the dose required to reduce blood glucose by 20-40% from baseline 15 min after i.p. insulin injection in 8 week old wt DBA/2J mice.

By 12 weeks of age, mice were fasted for 6 h with free access to water and euthanized by an i.p. injection of pentobarbital (200 mg/kg). Blood was collected by cardiac puncture, transferred to heparinized tube, spun and plasma store at -80°C. Plasma insulin and IGF-1 were quantified using the Ultrasensitive Mouse Insulin ELISA kit and Mouse IGF-1 ELISA kit (both Crystal Chem, both Crystal Chem, Downers Grove, IL, US), respectively, according to manufacturer's instructions. Plasma creatinine was measured using the creatinine enzymatic assay as previously described (18). Finally, kidneys were dissected and either snap-frozen in liquid nitrogen or fixed for histological and ultrastructural evaluation as described below.

#### *Urine collection and urinary albumin excretion*

To assess urinary albumin excretion, spot urine samples were collected biweekly and stored at -20°C. The urinary albumin-to-creatinine ratio (ACR) was quantified using the Mouse Albumin ELISA Quantification Set (Bethyl Laboratories, Montgomery, TX) and the Creatinine Companion kit (Exocell, Philadelphia, PA, US) according to manufacturer's instructions. Urinary albumin excretion was also assessed by gel electrophoresis. Briefly, urine samples (5 µl per well) and a BSA control (Sigma-Aldrich, Gillingham, UK) of 10 µg per well were separated in 12% Mini-PROTEAN TGX gels and proteins visualized by coomassie stain using Bio-Safe Coomassie G-250 Stain (both Bio-Rad, Hemel Hempstead, UK).

*Glomerular histopathology and ultrastructure*

For histopathological evaluation, dissected kidneys were fixed in 4% formalin at 4°C, dehydrated, embedded in paraffin and cut at 3 µm before staining with Periodic acid–Schiff (PAS) and Masson’s Trichrome (TRI) stains using kits (both Sigma-Aldrich) according to manufacturer’s instructions. Glomerulosclerosis was scored semi-quantitatively according to the percentage of the glomerular tuft occupied with PAS-positive and nuclei-free matrix. From each mouse, a minimum of 18 glomeruli were scored according to a 5 point scale using the following criteria: 0) normal glomerulus; 1) up to 25% matrix area; 2) 25-50% matrix area; 3) 50-75% matrix area – focal; 4) 75-100% matrix area – global.

For immunofluorescence staining, frozen kidneys were cut at ~8 µm using a freezing microtome and sections blocked with 5% normal goat serum in 0.3% Triton X-100/PBS before incubation with primary antibodies against nephrin (Acris, Hereford, Germany) and collagen IV (Abcam, Cambridge, UK). All sections were incubated with Alexa Fluor® 405 and 488-conjugated secondary antibodies in 3% BSA, 0.3% Triton X-100/PBS and mounted with Vectashield mounting medium (Vector Laboratories, Peterborough, UK) before imaging using a Leica SP5II confocal laser scanning microscope attached to a Leica DMI 6000 inverted epifluorescence microscope with a 63x oil immersion objective lens.

For evaluation of glomerular ultrastructure including foot process effacement and glomerular basement membrane thickening, ~1 mm<sup>3</sup> cubes from the renal cortex were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at 4°C. Samples were post-fixed in 1% osmium tetroxide in 0.1M sodium cacodylate buffer (pH 7.4) and en bloc stained in 3% aqueous uranyl acetate followed by dehydrated through a graded series of alcohol. Samples were embedded in Epon Resin and thin-sectioned at 70 nm. Digital micrographs were taken on a FEI Tecnai Spirit T12 (120KV) Transmission Electron Microscope (TEM).



## Statistical analyses

Data were modelled and groups compared using linear mixed-effects models in R (version 3.2.1; open source software available at [www.cran.r-project.org](http://www.cran.r-project.org)). Fixed effects (group, age, gender and strain) and random effects (mouse and litter) were included in the models as found appropriate. Longitudinal variables were analyzed as repeated measurements using the *lme* function to test for the effect of age and to compare groups, while variables that were independent of age and variables that were measured at one time-point only were analyzed using the *lmer* function. Model residuals and fitted values were tested for normality. In cases of non-normality, data were  $\log_{10}$ -transformed prior to modelling and group comparison. Linear correlation analyses were conducted in GraphPad Prism (version 6.05; GraphPad Software, La Jolla, CA). Unless stated otherwise, data are presented as means  $\pm$  standard error of the mean (SEM). Resulting P values are evaluated at a 5% significance level.

## Results

### *Metabolic phenotype of the db/db DBA/2J mouse*

Body weight and non-fasted blood glucose were monitored from 6-12 weeks of age in female and male db/db and wt DBA/2J mice to characterize the early development of obesity and hyperglycemia. The body weight was significantly higher in db/db vs wt females from 6 through 12 weeks of age (all  $P < 0.001$ , Fig. 1A) and reached a 96% increase by the end of the study period. Male db/db mice had increased body weight compared to wt mice at 8-12 weeks of age ( $P < 0.001$  at 8 and 10 weeks,  $P < 0.05$  at 12 weeks) reaching a 37% increase by 10 weeks after which the db/db males experienced a significant drop in body weight through to 12 weeks of age ( $P < 0.05$ ).

Non-fasted blood glucose was similar in all groups at 6-weeks of age but became significantly higher in db/db vs wt mice from 8 through to 12-weeks of age in both genders (all  $P < 0.001$ , Fig. 1B). Blood glucose did not increase significantly beyond 8-weeks in female and 10-weeks in male

db/db mice. Plasma insulin was measured only at 12 weeks of age and was significantly increased in female db/db vs wt mice ( $7.15 \pm 0.64$  vs  $0.29 \pm 0.03$  ng/ml,  $P < 0.001$ , Fig. 1C), while no significant difference was observed between male groups ( $2.25 \pm 0.98$  vs  $1.36 \pm 0.44$  ng/ml).

ITTs were conducted at 6, 8 and 12 weeks to assess systemic insulin resistance, which was quantified by the AUC from ITT curves in females (Fig. 2A) and males (Figs 2C). Systemic insulin resistance was significantly increased in female db/db vs wt mice by 6 weeks of age ( $P < 0.01$ , Fig. 2B) and by 8 weeks of age in males ( $P < 0.001$ , Fig. 2D). In both genders, insulin resistance worsened significantly from 6 through to 12 weeks of age (both  $P < 0.001$ ).

#### *Albuminuria correlates with systemic insulin resistance in the db/db DBA/2J mouse*

The development of albuminuria was explored in db/db DBA/2J mice from 6 to 12 weeks of age and quantified by the urinary ACR. Female db/db mice had significantly higher urinary ACR compared to wt controls through 6-12 weeks of age ( $P < 0.01$  by 6 weeks,  $P < 0.001$  by 8-12 weeks, Fig. 3A), while ACR was increased from 8 through to 12 weeks of age in male db/db vs wt mice (all  $P < 0.001$ , Fig. 3B). This correlates with the onset of systemic insulin resistance as presented in figure 2B and 2D, respectively. The statistical analyses showed no significant effect of gender on the ACR fold change between db/db and wt controls, but a significant effect of age was observed as ACR fold change increased from 5-fold by 6 weeks to 50-fold by 12 weeks of age ( $P < 0.001$ , Fig. 3C). To explore the association between albuminuria and metabolic parameters, we performed correlation analyses between urinary ACR and body weight, blood glucose and systemic insulin resistance, respectively. We observed significant positive correlations between ACR and all three metabolic parameters in both female and male mice (all  $P < 0.001$ , see  $R^2$  in Fig. 3D-F).

#### *Glomerular histopathology and ultrastructure in the db/db DBA/2J mouse*

To evaluate the glomerular histopathological changes in the db/db DBA/2J mouse, kidney sections were PAS, TRI and collagen-IV stained. Representative micrographs from 12-week old db/db and wt DBA/2J mice are presented in Fig. 4A. PAS stained sections showed glomerulosclerosis in the db/db mice, but not controls, at high magnification (second row - arrowed). Evaluation of TRI stained sections revealed that glomerular fibrosis was present when studying high magnification TRI stained micrographs (fourth row - arrowed). Finally, we observed type IV collagen accumulation in db/db, but not wild-type glomeruli (bottom row).

Semi-quantitative analysis was performed using glomerulosclerosis score (GS) in PAS stained kidney sections showed an increase in the percentage of glomeruli with  $GS \geq 1$  in db/db vs wt mice by 8 weeks of age (Fig. 4B). The mean GS was significantly increased in db/db vs wt DBA/2J mice at 8 and 12 weeks of age (both  $P < 0.001$ , Fig. 4C), whereas no significant worsening in GS was observed from 8 to 12 weeks in db/db DBA/2J mice. The mean GS correlated positively with urinary ACR in the DBA/2J cohort ( $P < 0.001$ ,  $R^2 = 0.7686$ , Fig. 4D).

Ultrastructural changes between 12-week old db/db and wild-type controls were evaluated by TEM and representative images are displayed in Fig. 5A (top row). Significant increases in podocyte foot process width ( $P < 0.05$ , Fig. 5B) and glomerular basement membrane (GBM) thickness ( $P < 0.001$ , Fig. 5C) were detected in db/db vs wt DBA/2J mice.

#### *Effects of genetic background on the metabolic phenotype in the db/db mouse model*

The metabolic phenotype of male db/db DBA/2J and BLKS/J mice was compared to explore the effects of genetic background on the phenotypical manifestation of the *db* allele. The body weight of db/db DBA/2J mice was 16-20% lower than db/db BLKS/J mice throughout the study period ( $P < 0.001$ , Table 2). Unlike db/db DBA/2J mice, db/db BLKS/J males did not demonstrate any weight loss during the study period although their body weight was unchanged from 10 weeks of

age. Non-fasted blood glucose were significantly lower in db/db DBA/2J mice at 8 weeks ( $P<0.001$ , Table 2), but reached similar levels to that of db/db BLKS/J mice by 12 weeks age. Systemic insulin resistance was significantly lower in db/db DBA/2J vs BLKS/J males at 8 and 12 weeks of age ( $P<0.001$  and  $P<0.05$ , respectively, Table 2). In wt mice, genetic background did not significantly affect the metabolic parameters presented in Table 2. Finally, comparisons of plasma insulin levels showed no significant differences between male DBA/2J and BLKS/J cohorts in either db/db ( $2.25\pm0.98$  vs  $4.64\pm2.45$  ng/ml) or wt mice ( $1.36\pm0.44$  vs  $1.11\pm0.2$  ng/ml).

#### *Effects of genetic background on kidney injury in the db/db mouse model*

To evaluate the effects of genetic background on the susceptibility to kidney injury, we compared albuminuria as well as renal structural and histopathological changes between male db/db DBA/2J and db/db BLKS/J mice. Qualitative analysis of urine samples by SDS-PAGE indicated increased urinary albumin concentrations in db/db DBA/2J vs db/db BLKS/J mice at 8 and 12 weeks of age (Fig. 6A). In addition, urinary ACR was significantly higher in db/db DBA/2J vs db/db BLKS/J mice ( $P<0.05$ , Fig. 6B) with ACR fold changes in db/db vs wt mice within the male DBA/2J cohort ranging from 32- to 44-fold compared with 16- to 18-fold in the BLKS/J2 cohort. Urinary concentrations of albumin were also significantly higher in DBA/2J vs BLKS/J db/db males ( $P<0.01$ , Fig. 6C).

Furthermore, the urinary creatinine concentrations were similar in db/db mice between strains, but significantly higher in BLKS/J vs DBA/2J wt mice ( $P<0.05$ , Fig. 6D). Finally, we assessed serum creatinine levels in a subset of DBA/2J and BLKS/J mice at 12 weeks of age. This revealed no significant differences between db/db and their wild-type controls on either the DBA/2J or BLKS/J backgrounds (Fig. 6E).

The impact of genetic background on kidney weights and glomerular histological changes was also investigated. Firstly, relative kidney weight was significantly reduced in db/db vs wt BLKS/J mice ( $P<0.001$ , Table 3), while no significant differences in kidney weight were observed

between DBA/2J groups. Between strains, relative, but not absolute kidney weight was significantly higher in db/db DBA/2J vs BLKS/J mice ( $P<0.01$ , Table 3).

Semi-quantitative histological evaluation showed increased GS in db/db vs wt mice by 12 weeks of age in both strains (both  $P<0.001$ , Table 3), whereas the glomerular area was significantly enlarged in db/db vs wt in the DBA/2J strain ( $P<0.001$ , Table 3), but not BLKS/J. Finally, comparison of the DBA/2J and BLKS/J cohorts showed no significant effect of genetic background on GS and glomerular area in db/db and in wt mice.

The effect of background strain on ultrastructural changes in glomeruli was evaluated by TEM and representative micrographs presented in Fig. 5A. In both strains, podocyte foot process width and GBM thickness was significantly increased in db/db vs wt mice (for both strains  $P<0.05$ , Fig. 5B and  $P<0.001$ , Fig. 5C, respectively). Furthermore, the width of foot processes was significantly higher in db/db BLKS/J vs DBA/2J mice ( $P<0.001$ , Fig.5B), while the GBM thickness did not differ between strains (Fig. 5C). No significant differences were observed between DBA/2J and BLKS/J wild-type mice.

## Discussion

DN research and drug development is challenged by the shortcomings of current animal models. Considerable resources are therefore invested in the development of novel animal models that reproduce features of human disease. In this study, we followed the advancement of early DN in the db/db DBA/2J mouse and found that it developed robust albuminuria starting between 6 and 8 weeks of age that correlated closely with systemic insulin resistance, body weight and blood glucose levels. We then compared male db/db DBA/2J mice with an age-matched cohort of male db/db BLKS/J mice, which is the major strain used in type-2 DN research, and found a significant effect of genetic background on the severity of urinary albumin excretion despite similar levels of hyperglycemia and systemic insulin resistance in both strains. This study underlines the impact of

genetic background on the propensity to renal injury in mouse models of diabetes and DN, and confirms the susceptibility of the DBA/2J strain to albuminuric kidney disease.

Like BLKS/J, the DBA/2J strain is susceptible to the diabetogenic actions of the *db* allele. This causes these mouse strains to develop overt type-2 diabetes with pancreatic exhaustion, beta-cell depletion and insulinopenia after a preceding period of systemic insulin resistance leading to pancreatic hypertrophy and hyperinsulinemia as in human type-2 diabetes patients. The duration of the gradual transition from systemic insulin resistance to overt diabetes-2 depend varies between mouse strains and gender (20). Here, we observed an early onset of hyperglycemia and systemic insulin resistance in female and male db/db DBA/2J mice at 6 and 8 weeks of age, respectively. As seen in various mouse models of diabetes (10, 20), males displayed accelerated advancement of the diabetic phenotype relative to females and developed severe hyperglycemia and insulinopenia resulting in weight loss starting at 10 weeks of age possibly due to glycosuria. In contrast, female db/db DBA/2J mice displayed sustained hyperinsulinemia by 12 weeks of age explaining the stabilized, although elevated, blood glucose levels through 8-12 weeks of age. Furthermore, the metabolic manifestations of the *db* allele - in terms of hyperglycemia and systemic insulin resistance - were similar in the male db/db DBA/2J and BLKS/J cohorts by 12 weeks of age. These data are consistent with previous studies by Leiter *et al.* who studied the metabolic parameters in DBA/2J and BLKS/J db/db mice and classified them “diabetes prone” in contrast to “diabetes-resistant” C57BL/6 mice (20).

In human patients as well as in animal models, albuminuria is used as the hallmark biomarker of DN. In mice, it has been shown that genetic factors modulate the levels of albuminuria in models of type-1 diabetes including the STZ-induced and Akita models (14, 29, 34) as well as in type-2 diabetes in the db/db model (31). In this study, we observed robust albuminuria by 8 weeks of age in both female and male db/db DBA/2J mice. Furthermore, we saw a development in albuminuria with ACR fold changes in db/db relative to age- and gender-

314 matched controls resulting in a 56-fold increase in females and a 44-fold increase in males by 12  
315 weeks of age. As far as we are aware this is the first study that has examined the development of  
316 albuminuria in the db/db model on a DBA2J background. We decided to compare this genetic  
317 strain to the most widely studied strain that develops early DN, BLKS/J. Importantly we studied  
318 both strains of mice in the same environment, using the same feeding regimen, and collected all  
319 samples in a similar manner. Despite these measures, the different vendors of the mouse strains  
320 cannot be excluded as a confounding factor. Our head-to-head strain comparison showed  
321 significantly higher levels of urinary albumin excretion in male db/db DBA/2J mice compared with  
322 db/db BLKS/J mice as assessed by urinary ACR. This feature was mainly driven by an increase in  
323 crude urinary albumin excretion rather than a reduction in urinary creatinine levels. Furthermore,  
324 although we didn't measure formal glomerular filtration rates in our mice we did measure serum  
325 creatinine levels in a subset of mice which were not significantly different. This suggests that there  
326 wasn't a major difference in the level of hyperfiltration between DBA2J and BLKS mice. GFRs have  
327 not been previously assessed in db/db DBA2J mice however they have been performed in BLKS  
328 db/db and wild-type mice. These studies have revealed either no difference in the level of GFR  
329 between these groups at 24 weeks (35) or a small increase in the db/db mice at 18 weeks (4). In  
330 the future it will be interesting to rigorously assess the progression of hyperfiltration in the db/db  
331 DBA2J model using formal GFR assessment but this wasn't the focus of this study.

332       Alongside albuminuria, features of DN in the db/db mouse include histopathological findings  
333 such as glomerulosclerosis and glomerular enlargement as well as ultrastructural changes  
334 including foot process effacement and GBM thickening. Our data showed that glomerulosclerosis  
335 was increased in db/db compared to wild-type DBA/2J mice by 8-weeks of age and glomerular  
336 enlargement was detectable by 12 weeks of age. Compared with the db/db BLKS/J cohort, we  
337 detected no differences in these features in the db/db DBA2J males. It has previously been  
338 described in mouse models of DN that increased levels of urinary albumin excretion do not

translate into exacerbation of histopathological changes (14, 28). This may simply be due to the superior sensitivity of the urinary albumin excretion relative to semi-quantitative histological analysis in detecting renal damage. Furthermore, the ultrastructural changes of the glomeruli described here do not explain the observed increase in ACR in db/db DBA/2J mice compared to the BLKS/J strain. Together, our data suggest that the increased susceptibility to albuminuria of the DBA/2J mouse may be caused by underlying genetic makeup leading to differences in the molecular susceptibility to albuminuric kidney disease.

We characterized the development of metabolic parameters during the transition from systemic insulin sensitivity to resistance, and through to overt diabetes. We observed positive correlations between ACR and systemic insulin resistance as well as glomerulosclerosis scores in the db/db DBA/2J mouse model. Clinically, these findings are potentially important as they mimic the association between microalbuminuria and insulin resistance observed in non-diabetic metabolic syndrome patients (24, 27) and in diabetic subjects (9, 15). Thus, our findings support the applicability of the db/db DBA/2J mouse to study these early stages of insulin resistant glomerulopathies and DN in order to decipher the pathophysiological events that may precede and accelerate the progression to late stage DN.

Together with a growing amount of experimental data from mouse models of diabetes (13, 14) and models of diet-induced obesity (32), the present study confirms the notion that DBA/2J display enhanced sensitivity to metabolically-induced albuminuria kidney disease. When compared to BLKS/J mice, at its onset, systemic insulin resistance was less in the db/db DBA/2J mice, but they exhibited significantly more albuminuria. This suggests that the inherent cellular insulin resistance in DBA/2J mice must be greater than that in the BLKS/J strain, which has previously been described by others (3). Studies have been conducted to identify genetic contributors to diabetes susceptibility in the db/db mouse model (8), but fail to distinguish diabetes and DN-susceptibility loci. Further genetic analyses are therefore required to identify



genes that are differentially expressed between the diabetes-prone DBA/2J and BLKS/J strains and that may explain the molecular difference underlying the present observations as previously achieved in a comparison between the DBA/2J and C57BL/6 strains (29). Finally, as the DBA/2J is a pure inbred strain, it is attractive as it will be possible to generate db/db mice carrying specific transgenes that can be back-crossed onto this albuminuric susceptible genetic background to decipher the molecular mechanisms of this underlying insulin resistance and the influence on the establishment and development of DN in the kidney, glomerulus and even in individual cell populations such as the podocytes in this kidney disease-prone strain.

In summary, we have demonstrated that the db/db DBA/2J mouse develops robust albuminuria by 8 weeks of age alongside histopathological features of early DN including glomerulosclerosis and glomerular enlargement by 8 and 12 weeks of age, respectively. This is closely linked to systemic insulin resistance. The observed correlations between albuminuria and metabolic parameters support the applicability of this model as a clinically relevant model for biomedical research and drug development in insulin resistant states, diabetes and early DN. Further studies are required to explore whether the DBA/2J background also display an enhanced acceleration of the progression to late stage DN in the db/db mouse model of diabetes.

## **Disclosure**

This study was supported financially by Novo Nordisk A/S. M.V. Østergaard, J. Worm and L.N. Fink are all current or former employees at Novo Nordisk A/S.

## **Acknowledgements**

We thank Stephan D. Bouman from Global Research, Novo Nordisk A/S, for counselling on *in vivo* animal procedures. We also thank Fern Barrington and Chris Neal from Bristol Renal, University of Bristol, for skillful support with animal breeding and genotyping, and ultrastructural analyses,

389 respectively. Finally, we thank the staff of the Histology Services Unit and the Wolfson Bioimaging  
390 Facility, University of Bristol, for technical support during this project. This work was supported by an  
391 MRC Senior Clinical Fellowship to RJC (MR/K010492/1.)

## References

1. **Alpers CE, and Hudkins KL.** Mouse models of diabetic nephropathy. *Curr Opin Nephrol Hy* 20: 278-284, 2011.
2. **Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, and Saito A.** Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na<sup>+</sup>-glucose cotransporter inhibitor T-1095. *Brit J Pharmacol* 132: 578-586, 2001.
3. **Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers AC, and Wasserman DH.** Glucose metabolism in vivo in four commonly used inbred mouse strains. *Diabetes* 57: 1790-1799, 2008.
4. **Bivona BJ, Park S, and Harrison-Bernard LM.** Glomerular filtration rate determinations in conscious type II diabetic mice. *Am J Physiol-Renal* 300: F618-F625, 2011.
5. **Brosius FC, III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, and Takahashi T.** Mouse models of diabetic nephropathy. *JAmSocNephrol* 20: 2503-2512, 2009.
6. **Cohen MP, Lautenslager GT, and Shearman CW.** Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. *Metabolism* 50: 1435-1440, 2001.
7. **Coleman DL.** Obese and Diabetes - 2 Mutant-Genes Causing Diabetes-Obesity Syndromes in Mice. *Diabetologia* 14: 141-148, 1978.

- 410 8. **Davis RC, Schadt EE, Cervino ACL, Peterfy M, and Lusis AJ.** Ultrafine mapping of SNPs  
411 from mouse strains C57BL/6J, DBA/2J, and C57BLKS/J for loci contributing to diabetes and  
412 atherosclerosis susceptibility. *Diabetes* 54: 1191-1199, 2005.
- 413 9. **De Cosmo S, Minenna A, Ludovico O, Mastroianno S, Di Giorgio A, Pirro L, and Trischitta**  
414 **V.** Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in  
415 patients with type 2 diabetes - Evidence of a sex-specific association. *Diabetes Care* 28: 910-915,  
416 2005.
- 417 10. **Franconi F, Seghieri G, Canu S, Straface E, Campesi I, and Malorni W.** Are the available  
418 experimental models of type 2 diabetes appropriate for a gender perspective? *Pharmacol Res* 57:  
419 6-18, 2008.
- 420 11. **Freedman BI, Bostrom M, Daeihagh P, and Bowden DW.** Genetic factors in diabetic  
421 nephropathy. *Clin J Am Soc Nephro* 2: 1306-1316, 2007.
- 422 12. **Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, and Eriksson J.** Insulin-  
423 Resistance, Hypertension and Microalbuminuria in Patients with Type-2 (Non-Insulin-Dependent)  
424 Diabetes-Mellitus. *Diabetologia* 36: 642-647, 1993.
- 425 13. **Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, and Coffman TM.** Impact of genetic  
426 background on nephropathy in diabetic mice. *American journal of physiology Renal physiology*  
427 290: F214-222, 2006.

- 428 14. **Gurley SB, Mach CL, Stegbauer J, Yang J, Snow KP, Hu A, Meyer TW, and Coffman TM.**  
429 Influence of genetic background on albuminuria and kidney injury in Ins2(+/-C96Y) (Akita) mice.  
430 *Am J Physiol Renal Physiol* 298: F788-F795, 2010.
- 431 15. **Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Tai TY, Yang HJ, Chang CT, Chang CJ, Li**  
432 **YS, Shin SJ, and Kuo KN.** Association Between Insulin Resistance and Development of  
433 Microalbuminuria in Type 2 Diabetes A prospective cohort study. *Diabetes Care* 34: 982-987, 2011.
- 434 16. **Hu FB, Li TY, Colditz GA, Willett WC, and Manson JE.** Television watching and other  
435 sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. *Jama-J*  
436 *Am Med Assoc* 289: 1785-1791, 2003.
- 437 17. **Hummel KP, Dickie MM, and Coleman DL.** Diabetes a New Mutation in Mouse. *Science*  
438 153: 1127-&, 1966.
- 439 18. **Keppler A, Gretz N, Schmidt R, Kloetzer HM, Groene HJ, Lelongt B, Meyer M, Sadick M,**  
440 **and Pill J.** Plasma creatinine determination in mice and rats: An enzymatic method compares  
441 favorably with a high-performance liquid chromatography assay. *Kidney Int* 71: 74-78, 2007.
- 442 19. **Leiter EH.** The influence of genetic background on the expression of mutations at the  
443 diabetes locus in the mouse IV. Male lethal syndrome in CBA/Lt mice. *Diabetes* 30: 1035-1044,  
444 1981.
- 445 20. **Leiter EH, Coleman DL, and Hummel KP.** The influence of genetic background on the  
446 expression of mutations at the diabetes locus in the mouse. III. Effect of H-2 haplotype and sex.  
447 *Diabetes* 30: 1029-1034, 1981.

- 448 21. **Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, and Tesch GH.** Antibody  
449 blockade of c-fms suppresses the progression of inflammation and injury in early diabetic  
450 nephropathy in obese db/db mice. *Diabetologia* 52: 1669-1679, 2009.
- 451 22. **Mao HZ, Roussos EI, and Peterfy M.** Genetic analysis of the diabetes-prone C57BLKS/J  
452 mouse strain reveals genetic contribution from multiple strains. *Bba-Mol Basis Dis* 1762: 440-446,  
453 2006.
- 454 23. **Mishra R, Emancipator SN, Miller C, Kern T, and Simonson MS.** Adipose differentiation-  
455 related protein and regulators of lipid homeostasis identified by gene expression profiling in the  
456 murine db/db diabetic kidney. *American journal of physiology Renal physiology* 286: F913-921,  
457 2004.
- 458 24. **Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, and Haffner SM.**  
459 Microalbuminuria is associated with insulin resistance in nondiabetic subjects - The insulin  
460 resistance atherosclerosis study. *Diabetes* 47: 793-800, 1998.
- 461 25. **Orchard TJ, Chang YF, Ferrell RE, Petro N, and Ellis DE.** Nephropathy in type I diabetes: A  
462 manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the  
463 Pittsburgh Epidemiology of Diabetes Complication Study. *Kidney Int* 62: 963-970, 2002.
- 464 26. **Palmer ND, and Freedman BI.** Insights into the Genetic Architecture of Diabetic  
465 Nephropathy. *Curr Diabetes Rep* 12: 423-431, 2012.

- 466 27. **Pilz S, Rutters F, Nijpels G, Stehouwer CDA, Hojlund K, Nolan JJ, Balkau B, Dekker JM,**  
467 **and Investigators R.** Insulin Sensitivity and Albuminuria: The RISC Study. *Diabetes Care* 37: 1597-  
468 1603, 2014.
- 469 28. **Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, and Breyer MD.** Characterization of  
470 susceptibility of inbred mouse strains to diabetic nephropathy. *Diabetes* 54: 2628-2637, 2005.
- 471 29. **Sheehan S, Tsaih SW, King BL, Stanton C, Churchill GA, Paigen B, and DiPetrillo K.**  
472 Genetic analysis of albuminuria in a cross between C57BL/6J and DBA/2J mice. *Am J Physiol-Renal*  
473 293: F1649-F1656, 2007.
- 474 30. **Susztak K, Raff AC, Schiffer M, and Bottinger EP.** Glucose-induced reactive oxygen  
475 species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic  
476 nephropathy. *Diabetes* 55: 225-233, 2006.
- 477 31. **Tesch GH, and Lim AKH.** Recent insights into diabetic renal injury from the db/db mouse  
478 model of type 2 diabetic nephropathy. *Am J Physiol-Renal* 300: F301-F310, 2011.
- 479 32. **Wicks SE, Nguyen T-T, Breaux C, Kruger C, and Stadler K.** Diet-induced obesity and kidney  
480 disease - In search of a susceptible mouse model. *Biochimie* 2015.
- 481 33. **Wild S, Roglic G, Green A, Sicree R, and King H.** Global prevalence of diabetes - Estimates  
482 for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047-1053, 2004.

483 34. **Wu X, Davis RC, McMillen TS, Schaeffer V, Zhou Z, Qi H, Mazandarani PN, Alialy R,**  
484 **Hudkins KL, Lusic AJ, and LeBoeuf RC.** Genetic modulation of diabetic nephropathy among mouse  
485 strains with Ins2 Akita mutation. *Physiol Rep* 2: 2014.

486 35. **Zhao HJ, Wang SW, Cheng HF, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, and Harris**  
487 **RC.** Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic  
488 mice. *Journal of the American Society of Nephrology* 17: 2664-2669, 2006.

489



## Figure Legends

**Figure 1 | Metabolic phenotype of the db/db DBA/2J mouse.** **A |** Body weight and **B |** non-fasted blood glucose in female and male db/db DBA/2J mice and wt controls from 6-12 weeks of age. Data are mean  $\pm$  SEM, n=7-12. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001: Within same gender and age, groups are significantly different. **C |** Plasma insulin in female and male db/db DBA/2J mice and wt controls at 12 weeks of age. Data are mean  $\pm$  SEM, n=3-5. \*\*\*P<0.001: Within same gender, groups are significantly different.

**Figure 2 | Systemic insulin resistance in the db/db DBA/2J mouse.** Systemic insulin resistance as assessed by Insulin Tolerance Tests (ITT) in female and male db/db and wt DBA/2J mice at 6, 8 and 12 weeks of age. **A, C |** Mice were fasted for 6 h and blood glucose measured before and after intraperitoneal administration of insulin (0.20 IU/kg in females, 0.50 IU/kg in males). **B, D |** Systemic insulin resistance quantified as Area under the curve (AUC) from ITT curves in females and males, respectively. Data are mean  $\pm$  SEM, n = 3-11. \*\*P<0.01, \*\*\*P<0.001: At individual time-points, groups are significantly different.

**Figure 3 | Urinary albumin excretion in the db/db DBA/2J mouse.** Development of urinary albumin excretion quantified as the albumin-to-creatinine ratio (ACR) in spot urine samples from **A |** female and **B |** male db/db DBA/2J mice and wt controls through 6-12 weeks of age. Dots represent individual animals and lines indicate medians, n = 4-12. \*\*P<0.01, \*\*\*P<0.001: At individual time-points, groups are significantly different. **C |** ACR fold change in db/db relative to gender and age-matched wt controls. Bars are mean  $\pm$  SEM, n = 4-12. \*\*\*P<0.001: Independent of gender, significant difference between time-points. **D-F |** Correlations between urinary ACR and **D |** body weight, **E |** non-fasted blood glucose and **F |** systemic insulin resistance in the db/db DBA/2J mouse. Dots represent individual animals and lines are fitted by linear regression within

each gender ( $\ominus$  females,  $\oplus$  males). All correlations are statistical significant ( $P < 0.001$ ,  $R^2$  are given in individual graphs),  $n = 34-71$ .

**Figure 4 | Renal histopathology in the db/db DBA/2J mouse. A |** Representative micrographs of renal cortex and glomeruli from db/db and wt DBA/2J mice by 12 weeks of age stained with Periodic acid-Schiff and Masson's trichrome as well as nephrin and collagen IV antibodies. All scale bars are 50  $\mu$ m. **B |** Distribution of glomerulosclerosis scores (GS) in db/db DBA/2J mice by 8 ( $n = 2$ ) and 12 weeks of age ( $n = 4$ ) compared with wt DBA/2J controls ( $n = 6$ , compiled across 8-12 weeks of age). **C |** Mean GS in db/db DBA/2J and wt mice at 8 and 12 weeks of age. Bars are mean  $\pm$  SEM,  $n = 2-4$ . \*\*\* $P < 0.001$ : At individual time-points, groups are significantly different. **D |** Correlation between urinary ACR and mean GS. Dots represent individual animals ( $n = 16$ ), the correlation was fitted by linear regression ( $P < 0.001$ ,  $R^2 = 0.7686$ ) and the dotted line indicate the 95% confidence interval.

**Figure 5 | Glomerular ultrastructure in the db/db mouse model.** The ultrastructural changes of glomeruli were evaluated by transmission electron microscopy (TEM) at 12 weeks of age. **A |** Representative TEM micrographs of podocyte foot processes and the glomerular basement membrane (GBM) in 12 week old wt and db/db DBA/2J and BLKS/J mice. Glomeruli were systematically evaluated to quantify **B |** the podocyte foot process width and **C |** the GBM thickness in wt and db/db both within and between mouse strains. Bars are means  $\pm$  SEM. \* $P < 0.05$ , \*\*\* $P < 0.001$ : Groups are significantly different.

**Figure 6 | Modulation of urinary albumin excretion by genetic background in the db/db mouse model.** The urinary albumin excretion was evaluated in spot urine samples from male db/db and wt DBA/2J and BLKS/J mice through 8-12 weeks of age. **A |** Evaluation by SDS-PAGE (5  $\mu$ l urine per

540 lane) followed by comassie stain using BSA (~66kDa) as positive control. Urinary **B** | ACR and **C** |  
541 albumin concentrations in spot urine samples. Dots represent individual animals (n = 4-12) and  
542 lines indicate medians. **D** | Urinary creatinine concentrations in spot urine samples. Bars are mean  
543  $\pm$  SEM, n = 4-12. \*P<0.05, \*\*P<0.01: Within same group, strains are significantly different. **E** | Dot  
544 blot of serum creatinine measured in 12 week old mice. Analyzed with a one-way ANOVA revealed  
545 no significant difference between any groups. N=3-6 for each group.

## 546 Tables

547 **Table 1 |** DBA/2J breeding outcome

		Female	Male	Total
Litters		-	-	12
Mice per litter (mean)		2.7	2.8	5.5
Gender (fraction)		0.49	0.51	1.00
	<b>db/db</b>	0.32	0.41	0.36
Genotype (fraction)	<b>db/wt</b>	0.52	0.44	0.48
	<b>wt/wt</b>	0.16	0.15	0.16

548 **Table 2 |** Metabolic parameters in the DBA/2J and BLKS/J db/db mouse models

	Body weight (g)		Non-fasted blood glucose (mM)		Area under Curve (mM*min)	
	wt	db/db	wt	db/db	wt	db/db
8 weeks						
DBA/2J	24.0±1.5	33.1±0.7*†	7.88±0.39	16.94±2.09*†	450.9±64.2	1007.3±87.4*†
BLKS/J	25.7±0.5	39.7±0.8*	6.95±0.29	26.05±1.52*	372.4±20.2	2264.8±147.5*
10 weeks						
DBA/2J	25.5±1.6	34.9±0.7*†	7.75±0.45	27.31±1.19*	ND	ND
BLKS/J	27.8±0.8	42.2±0.9*	7.30±0.32	29.9±1.21*	ND	ND
12 weeks						
DBA/2J	27.3±1.5	33.0±1.1*†	7.77±0.32	31.01±0.86*	402.3±42.8	1836.8±326.1*†
BLKS/J	28.7±0.8	42.1±1.2*	7.10±0.21	28.63±1.21*	405.9±15.3	2530.5±121.0*




549 Data are mean ± SEM, n = 3-12 for DBA/2J mice, n = 6 for BLKS/J mice. \*P<0.001: Within same strain and age, groups  
550 are significantly different. †P<0.05, ‡P<0.001: Within same group and age, strains are significantly different. ND: Not  
551 determined.





552 **Table 3 |** Kidney weights and glomerular structure in the DBA/2J and BLKS/J db/db mouse models

	Absolute weight (g)		Relative weight (mg kidney/g body weight)		Mean glomerulosclerosis score		Glomerular area ( $\mu\text{m}^2$ )	
	wt	db/db	wt	db/db	wt	db/db	wt	db/db
<b>DBA/2J</b>	0.489 $\pm$ 0.034 <sup>†</sup>	0.524 $\pm$ 0.068	18.42 $\pm$ 0.71 <sup>‡</sup>	16.79 $\pm$ 3.17 <sup>‡</sup>	0.21 $\pm$ 0.10	1.35 $\pm$ 0.13*	3878 $\pm$ 86	4653 $\pm$ 238*
<b>BLKS/J</b>	0.379 $\pm$ 0.016	0.410 $\pm$ 0.024	13.77 $\pm$ 0.51	9.78 $\pm$ 0.63*	0.45 $\pm$ 0.13	1.47 $\pm$ 0.10*	4274 $\pm$ 197	4765 $\pm$ 220


553 Data are mean  $\pm$  SEM, n = 4-6. \* $P$ <0.001: Within same strain, significant difference between groups. <sup>†</sup> $P$ <0.05, <sup>‡</sup> $P$ <0.01:





554 Within same group, strains are significantly different.




















**A****B****C****D****E**